Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. reduced its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 78.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,427 shares of the biotechnology company's stock after selling 257,884 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.33% of Enanta Pharmaceuticals worth $405,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. RA Capital Management L.P. bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth $5,968,000. Marshall Wace LLP lifted its stake in Enanta Pharmaceuticals by 9.3% in the fourth quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock worth $5,348,000 after acquiring an additional 79,197 shares during the period. Dimensional Fund Advisors LP grew its holdings in Enanta Pharmaceuticals by 52.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 297,106 shares of the biotechnology company's stock worth $1,708,000 after acquiring an additional 102,646 shares in the last quarter. Trexquant Investment LP increased its position in Enanta Pharmaceuticals by 97.3% during the 4th quarter. Trexquant Investment LP now owns 135,954 shares of the biotechnology company's stock valued at $782,000 after purchasing an additional 67,040 shares during the period. Finally, Wellington Management Group LLP increased its position in Enanta Pharmaceuticals by 47.6% during the 4th quarter. Wellington Management Group LLP now owns 51,298 shares of the biotechnology company's stock valued at $295,000 after purchasing an additional 16,547 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. Finally, JMP Securities increased their price target on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the company a "market outperform" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $18.00.

Enanta Pharmaceuticals Stock Up 3.6%

Shares of NASDAQ:ENTA traded up $0.26 during trading on Friday, hitting $7.47. The stock had a trading volume of 118,893 shares, compared to its average volume of 285,218. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $17.24. The stock has a market capitalization of $159.69 million, a price-to-earnings ratio of -1.51 and a beta of 0.81. The stock has a 50-day simple moving average of $5.49 and a two-hundred day simple moving average of $6.21.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. The business had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. As a group, sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.